Scarica l'app Stockscreener
128.53
0.70%
-0.92
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$129.45
Aprire:
$129.53
Volume 24 ore:
3.79M
Relative Volume:
0.60
Capitalizzazione di mercato:
$223.56B
Reddito:
$43.11B
Utile/perdita netta:
$13.94B
Rapporto P/E:
16.07
EPS:
7.9963
Flusso di cassa netto:
$6.78B
1 W Prestazione:
-3.58%
1M Prestazione:
-3.18%
6M Prestazione:
-0.89%
1 anno Prestazione:
+9.10%
Intervallo 1D:
$128.31
$131.16
Intervallo di 1 settimana:
$125.74
$134.50
Portata 52W:
$110.86
$140.84
Abbott Laboratories Stock (ABT) Company Profile
Nome
Abbott Laboratories
Settore
Industria
Telefono
(224) 667-6100
Indirizzo
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Confronta ABT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
128.45 | 231.95B | 43.11B | 13.94B | 6.78B | 7.9963 |
|
BSX
Boston Scientific Corp
|
97.94 | 142.60B | 18.49B | 2.50B | 3.49B | 1.6801 |
|
SYK
Stryker Corp
|
367.46 | 141.45B | 23.82B | 2.92B | 4.02B | 7.5574 |
|
MDT
Medtronic Plc
|
95.18 | 123.83B | 34.20B | 4.69B | 5.30B | 3.6218 |
|
EW
Edwards Lifesciences Corp
|
72.85 | 43.07B | 5.69B | 1.41B | 577.90M | 6.9828 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-10 | Iniziato | The Benchmark Company | Buy |
| 2025-07-18 | Aggiornamento | Jefferies | Hold → Buy |
| 2025-06-16 | Iniziato | Leerink Partners | Market Perform |
| 2024-10-08 | Iniziato | Oppenheimer | Outperform |
| 2024-09-19 | Iniziato | Piper Sandler | Overweight |
| 2024-07-30 | Downgrade | Edward Jones | Buy → Hold |
| 2024-05-30 | Iniziato | Goldman | Buy |
| 2023-07-21 | Aggiornamento | Wolfe Research | Underperform → Peer Perform |
| 2023-05-30 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2023-04-20 | Reiterato | Barclays | Overweight |
| 2023-04-20 | Reiterato | Bernstein | Outperform |
| 2023-04-20 | Reiterato | JP Morgan | Overweight |
| 2023-04-20 | Reiterato | Raymond James | Outperform |
| 2023-04-20 | Reiterato | UBS | Buy |
| 2023-04-20 | Reiterato | Wolfe Research | Underperform |
| 2023-03-29 | Iniziato | UBS | Buy |
| 2022-10-26 | Iniziato | Mizuho | Neutral |
| 2022-10-18 | Iniziato | Barclays | Overweight |
| 2022-10-12 | Iniziato | Jefferies | Hold |
| 2022-07-06 | Iniziato | Wolfe Research | Underperform |
| 2022-03-02 | Ripresa | BofA Securities | Buy |
| 2022-01-27 | Reiterato | Credit Suisse | Outperform |
| 2022-01-27 | Reiterato | Morgan Stanley | Overweight |
| 2022-01-27 | Reiterato | Raymond James | Outperform |
| 2022-01-27 | Reiterato | UBS | Buy |
| 2021-12-10 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-10-27 | Aggiornamento | Atlantic Equities | Neutral → Overweight |
| 2021-10-14 | Iniziato | Redburn | Neutral |
| 2021-05-25 | Iniziato | Barclays | Overweight |
| 2021-04-15 | Iniziato | Atlantic Equities | Neutral |
| 2021-01-28 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2020-09-11 | Iniziato | Wolfe Research | Outperform |
| 2020-06-01 | Downgrade | Goldman | Neutral → Sell |
| 2020-03-05 | Iniziato | Citigroup | Buy |
| 2020-02-13 | Iniziato | Goldman | Neutral |
| 2020-02-06 | Ripresa | BTIG Research | Neutral |
| 2020-01-02 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-06-13 | Reiterato | BofA/Merrill | Buy |
| 2019-02-07 | Reiterato | BofA/Merrill | Buy |
| 2019-01-02 | Downgrade | Citigroup | Neutral → Sell |
| 2018-11-30 | Aggiornamento | Goldman | Neutral → Buy |
| 2018-10-16 | Iniziato | Barclays | Overweight |
| 2018-06-27 | Iniziato | Bernstein | Outperform |
| 2018-01-30 | Reiterato | Citigroup | Neutral |
| 2018-01-25 | Reiterato | Stifel | Buy |
| 2018-01-25 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2018-01-03 | Iniziato | Evercore ISI | Outperform |
| 2018-01-02 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2018-01-02 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2017-10-19 | Reiterato | RBC Capital Mkts | Outperform |
| 2017-10-19 | Reiterato | Stifel | Buy |
Mostra tutto
Abbott Laboratories Borsa (ABT) Ultime notizie
Abbott (ABT) Margin Surge Reinforces Bullish Narratives Despite Earnings Decline Forecast - Yahoo
Abbott Laboratories’ Earnings Call Highlights Strong Growth - TipRanks
Strong Performance and Future Potential: Buy Rating for Abbott Laboratories - TipRanks
Why Abbott Laboratories (ABT) Stock Is Down Today - The Globe and Mail
Gold Gains Over 1%; Abbott Shares Fall After Q3 Results - Benzinga
Abbott Laboratories (ABT) Q3 2025 Earnings Call Highlights: Stro - GuruFocus
Abbott narrows outlook, Australian stocks react to US-China trade - Yahoo Finance
Abbott Laboratories (ABT) Sees Robust Growth in Q3 2025 - GuruFocus
Abbott CEO: ‘We’re right on time’ to the PFA party - MedTech Dive
Abbott Q3 results come up shy of sales forecast, Medical Device sales grow 15% - MassDevice
Abbott Laboratories' Q3 2025 Results: Steady Performance with Limited Upside - GuruFocus
Is it Time to Buy the Abbott Labs Dip? - TheStreet Pro
Abbott Labs Q3 2025 presentation: organic growth solid despite market challenges - Investing.com Australia
Earnings call transcript: Abbott Labs Q3 2025 sees stable EPS, stock dips - Investing.com
Abbott revenue misses as diagnostics, nutrition weakness clouds medical devices lift - Reuters
Abbott Laboratories Remains In Favor With London Investment Manager, New Filing Shows - The Motley Fool
Abbott (ABT) Stock Slides on Mixed Q3 Results – Is a Rally Over? - ts2.tech
Medical device business accelerates but diagnostics 'lose momentum'; Abbott Laboratories' performance falls short of expectations. - 富途牛牛
1 No-Brainer Dividend Stock to Buy and Hold Forever - AOL.com
Abbott (ABT) Stock Falls Despite Meeting Earnings Expectations – Here’s Why - parameter.io
Abbott's Q3 Earnings Meet Estimates, Revenues Up Y/Y, Stock Climbs - Yahoo Finance
S&P Health Giant Skids On Mixed Third-Quarter News - Investor's Business Daily
Abbott Laboratories posts steady sales growth in Q3, reaffirms full-year guidance - Proactive financial news
ABT Sees Growth from New Products and Biosimilars - GuruFocus
Abbott Cuts Top End of 2025 Guidance as Tariff Threat Looms - Bloomberg.com
Abbott Laboratories reports results for the quarter ended September 30Earnings Summary - TradingView
Here's What Key Metrics Tell Us About Abbott (ABT) Q3 Earnings - Yahoo
Abbott Tightens Annual Sales Forecast As Q3 Sales Miss Expectations - inkl
Abbott Laboratories Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 - MarketScreener
Abbott Laboratories (ABT) Faces Revenue Shortfall Despite Earnin - GuruFocus
Abbott Laboratories (ABT) Anticipates Earnings Surge - GuruFocus
Stock Market Today: S&P 500, Nasdaq Futures Rise— Bank Of America, Morgan Stanley, Abbott Earnings In Focus (UPDATED) - Benzinga
Abbott Laboratories Revises Annual Earnings Outlook In Line With View; Stock Down In Pre-Market - Nasdaq
Abbott Posts Steady Growth As Medical Devices Shine - Finimize
Earnings Snapshot: Abbott Laboratories Q3 misses revenue estimates; narrows FY profit outlook range - MSN
Abbott in charts: Medical Devices continues to see Y/Y double-digit growth momentum in Q3, up 14.8% - MSN
Abbott Laboratories down after Q3 topline miss - MSN
Abbott Posts Solid Earnings, Adult Nutrition Drives Sales. The Stock Drops Anyway. - MSN
Abbott (ABT) Q3 Earnings Meet Estimates - Yahoo
Abbott revenue falls short of estimates on weak demand for diagnostic devices - Yahoo
Abbott Laboratories stock down on Q3 topline miss (ABT:NYSE) - Seeking Alpha
Abbott Reaffirms Earnings Guidance for the Year 2025 - MarketScreener
Abbott misses revenue expectations on weak demand for diagnostic devices - MSN
Abbott Laboratories (ABT) Reports Mixed Q3 Results - GuruFocus
Abbott (ABT) Maintains 2025 Sales and EPS Forecasts - GuruFocus
Abbott (ABT) Posts Slight Miss on Q3 Revenue Expectations - GuruFocus
Abbott Laboratories Q3 Earnings: Adjusted EPS of $1.30 Beats Est - GuruFocus
Abbott reports in-line third-quarter results, affirms guidance; shares slip - Investing.com
Abbott Laboratories (NYSE:ABT) Reports Q3 In Line With Expectations - TradingView
Abbott Labs Posts Higher Sales, Reaffirms Outlook - The Wall Street Journal
Abbott Laboratories Q3 Adjusted Earnings, Net Sales Rise; Fiscal 2025 Non-GAAP EPS Guidance Narrowed - MarketScreener
Abbott Laboratories Azioni (ABT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.45%
0.42%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):